Eli Lilly's experimental "triple-G" drug, retatrutide, has shown significant results in reducing blood sugar and weight in diabetes trials, but it also raises some concerns. Meanwhile, Azalea Therapeutics is making progress towards in vivo CAR-T therapy, which could revolutionize cancer treatment by engineering T cells directly in the body.
Azalea Therapeutics, a company founded by Jennifer Doudna, has made significant strides towards in vivo CAR-T therapy, which involves engineering cancer-fighting T cells directly inside the body. This development could potentially streamline and expedite the CAR-T cell therapy process, offering a more efficient alternative to the traditional lab-driven methods. This advancement represents a promising investment opportunity in the emerging field of in vivo gene editing for cancer treatment.